Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Revance Therapeutics, Inc. - Common Stock (NQ: RVNC )

3.650 UNCHANGED
Last Price Updated: 4:00 PM EST, Feb 5, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Revance Therapeutics, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9
...
16 17 Next >
Revance Reports Third Quarter 2023 Financial Results, Provides Corporate Update
From Revance Therapeutics, Inc.
Via Business Wire
Revance Appoints Erica Jordan as Chief Commercial Officer, Aesthetics
From Revance Therapeutics, Inc.
Via Business Wire
Revance Therapeutics's Earnings Outlook
Via Benzinga
The Latest Analyst Ratings for Revance Therapeutics
Via Benzinga
Revance to Participate in Upcoming Investor Conferences
From Revance Therapeutics, Inc.
Via Business Wire
Analyst Ratings for Revance Therapeutics
Via Benzinga
The Latest Analyst Ratings for Revance Therapeutics
Via Benzinga
What's Going On With Botox Rival Revance Therapeutics' Stock Today?
Revance Therapeutics Inc (NASDAQ: RVNC) commenced a plan to exit the 
Via Benzinga
Revance to Release Third Quarter 2023 Financial Results on Wednesday, November 8, 2023
From Revance Therapeutics, Inc.
Via Business Wire
DAXXIFY® Becomes First Facial Injectable to be Named to TIME’s Best Inventions
From Revance Therapeutics, Inc.
Via Business Wire
Discontinuation Of Opul Business Weighs On Botox Rival Revance Therapeutics: Analyst Sees Non-Cash Impairment Charge In Millions
Needham analyst Serge Belanger reiterated a Buy rating on Revance Therapeutics, Inc. (NASDAQ: RVNC), 
Via Benzinga
Pinterest To Rally Around 45%? Here Are 10 Other Analyst Forecasts For Wednesday
Rosenblatt increased the price target for Pinterest, Inc. (NYSE: PINS) from $35 to $38. Rosenblatt analyst Barton Crockett maintained a Buy rating. Pinterest shares rose 3.2% to close at $26.21 on... 
Via Benzinga
Why Fresh Tracks Therapeutics Shares Are Trading Higher By Around 53%; Here Are 20 Stocks Moving Premarket
Gainers TransCode Therapeutics, Inc. (NASDAQ: RNAZ) shares rose 70.2% to $0.8937 in pre-market trading after falling 10% on Tuesday. 
Via Benzinga
Instacart, ARS Pharmaceuticals And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session
U.S. stock futures traded higher this morning on Wednesday. Here are some big stocks recording losses in today’s pre-market trading session. 
Via Benzinga
Dow Falls 150 Points; AutoZone Earnings Top Views
U.S. stocks traded lower toward the end of trading, with the Dow Jones falling more than 150 points on Tuesday. The Dow traded down 0.48% to 34,457.36 while the NASDAQ fell 0.28% to 13,672.29. The S&P... 
Via Benzinga
Topics Stocks
Exposures US Equities
Why Terran Orbital Shares Are Trading Lower By 19%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
Gainers Connexa Sports Technologies Inc. (NASDAQ: CNXA) shares jumped 124.2% to $0.1697 after falling 15% on Monday. 
Via Benzinga
Stocks That Hit 52-Week Lows On Tuesday
  During Tuesday's session, 275 companies made new 52-week lows. 
Via Benzinga
Crude Oil Rises Over 1%; Revance Therapeutics Shares Plummet
U.S. stocks traded lower midway through trading, with the Dow Jones falling more than 200 points on Tuesday. The Dow traded down 0.69% to 34,384.29 while the NASDAQ fell 0.82% to 13,597.78. The S&P 500... 
Via Benzinga
Topics Stocks
Exposures Fossil Fuels US Equities
Former IBD 50 Stock Revance Implodes As Its 'Prestige' Plan Goes Up In Smoke
The company is still figuring out how to gain share in a market topped by AbbVie. 
Via Investor's Business Daily
Markets Open Lower; US Housing Starts Fall In August
U.S. stocks traded lower this morning, with the Dow Jones falling around 40 points on Tuesday. Following the market opening Tuesday, the Dow traded down 0.12% to 34,581.70 while the NASDAQ fell 0.33%... 
Via Benzinga
Topics Stocks
Exposures US Equities
Revance Provides Corporate Update at Investor Day
From Revance Therapeutics, Inc.
Via Business Wire
3 Healthcare Stocks to Sell in September Before They Crash & Burn
The prognosis for these healthcare stocks isn't optimistic so plan to sell them this month before they get worse. 
Via InvestorPlace
3 Very Oversold Biotech Stocks to Buy Right Now
These biotech stocks have tumbled a great deal in recent months, but their long-term outlooks remain quite strong. 
Via InvestorPlace
Stocks That Hit 52-Week Lows On Monday
  Monday's session saw 175 companies set new 52-week lows. 
Via Benzinga
3 Very Oversold Pharma Stocks to Buy Right Now
Oversold pharma stocks have great total return potential. In this article, we list some of the best to buy. 
Via InvestorPlace
Revance to Host Investor Day on September 19, 2023
From Revance Therapeutics, Inc.
Via Business Wire
Stocks That Hit 52-Week Lows On Friday
  Friday's session saw 225 companies set new 52-week lows. 
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For August 16, 2023
Via Benzinga
Stocks That Hit 52-Week Lows On Thursday
  On Thursday, 283 companies set new 52-week lows. 
Via Benzinga
How Revance Is Taking A Page Out Of AbbVie's Botox Playbook
The company sells a cosmetic treatment. Now, it's bridging into neuroscience. 
Via Investor's Business Daily
< Previous 1 2 3 4 5 6 7 8 9
...
16 17 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.